--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc.:
What: Oral Presentation of Preliminary Two-Year Long-Term Follow-Up Study Results from Phase 2 Trials with ATX-101 for the Reduction of Localized Fat.
Poster Presentation of Results from a Phase 2B Study with ATX-101 Using Investigator, Subject and Magnetic Resonance Imaging Assessments
What: Oral Presentation of Preliminary Two-Year Long-Term Follow-Up Study Results from Phase 2 Trials with ATX-101 for the Reduction of Localized Fat.
Poster Presentation of Results from a Phase 2B Study with ATX-101 Using Investigator, Subject and Magnetic Resonance Imaging Assessments